Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$160.61
+0.6%
$174.59
$130.96
$182.89
$284.38B0.585.62 million shs2.33 million shs
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$107.33
-0.2%
$113.64
$89.67
$121.64
$186.24B0.745.60 million shs804,199 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
0.00%-4.08%-12.34%-2.64%+5.62%
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.00%+0.23%-5.39%-5.22%-2.66%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbbVie Inc. stock logo
ABBV
AbbVie
4.9775 of 5 stars
3.43.04.23.93.72.52.5
Abbott Laboratories stock logo
ABT
Abbott Laboratories
4.9896 of 5 stars
3.35.04.24.52.62.52.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.77
Moderate Buy$174.928.91% Upside
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.67
Moderate Buy$121.5013.20% Upside

Current Analyst Ratings

Latest ABT and ABBV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/29/2024
AbbVie Inc. stock logo
ABBV
AbbVie
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$195.00 ➝ $187.00
4/29/2024
AbbVie Inc. stock logo
ABBV
AbbVie
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$195.00 ➝ $180.00
4/24/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$124.00
4/22/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$141.00 ➝ $140.00
4/18/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$128.00 ➝ $125.00
4/4/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$120.00 ➝ $125.00
4/3/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$126.00 ➝ $128.00
3/27/2024
AbbVie Inc. stock logo
ABBV
AbbVie
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$185.00 ➝ $195.00
3/22/2024
AbbVie Inc. stock logo
ABBV
AbbVie
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$188.00 ➝ $190.00
2/14/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$128.00
2/6/2024
AbbVie Inc. stock logo
ABBV
AbbVie
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$180.00 ➝ $195.00
(Data available from 4/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$54.32B5.24$15.92 per share10.09$5.78 per share27.79
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$40.11B4.64$6.35 per share16.90$22.36 per share4.80

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.86B$3.3747.6613.242.0311.02%165.18%14.40%7/25/2024 (Estimated)
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$5.72B$3.2133.4420.962.5913.96%20.32%10.59%7/18/2024 (Estimated)

Latest ABT and ABBV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/26/2024Q1 24
AbbVie Inc. stock logo
ABBV
AbbVie
$2.26$2.31+$0.05$3.85$11.93 billion$12.31 billion    
4/17/2024Q1 24
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$0.96$0.98+$0.02$1.26$9.88 billion$9.96 billion    
2/2/202412/31/2023
AbbVie Inc. stock logo
ABBV
AbbVie
$2.76$2.79+$0.03$5.12$14.02 billion$14.30 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.203.86%+7.84%183.98%52 Years
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.202.05%+12.31%68.54%53 Years

Latest ABT and ABBV Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/15/2024
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.553.54%4/12/20244/15/20245/15/2024
2/16/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.551.9%4/12/20244/15/20245/15/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
5.02
0.87
0.76
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.35
1.64
1.16

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.25%
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.47%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
50,0001.77 billion1.77 billionOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
114,0001.74 billion1.73 billionOptionable

ABT and ABBV Headlines

SourceHeadline
Abbott Laboratories (NYSE:ABT) Shares Sold by Montag & Caldwell LLCAbbott Laboratories (NYSE:ABT) Shares Sold by Montag & Caldwell LLC
marketbeat.com - April 29 at 12:03 PM
Greg Abbott Issues Deadly Alligator Warning to MigrantsGreg Abbott Issues Deadly Alligator Warning to Migrants
msn.com - April 29 at 9:29 AM
Abbotts Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the KneeAbbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee
prnewswire.com - April 29 at 9:00 AM
Abbott sees a lot of positives in start vs. RangersAbbott sees 'a lot of positives' in start vs. Rangers
mlb.com - April 29 at 12:23 AM
Retirement Systems of Alabama Cuts Stock Position in Abbott Laboratories (NYSE:ABT)Retirement Systems of Alabama Cuts Stock Position in Abbott Laboratories (NYSE:ABT)
marketbeat.com - April 28 at 7:33 PM
Texas on High Alert: Governor Abbott Mobilizes Emergency Resources Amid Severe Weather WarningsTexas on High Alert: Governor Abbott Mobilizes Emergency Resources Amid Severe Weather Warnings
hoodline.com - April 28 at 2:21 PM
2 Beaten-Down Dividend Stocks to Buy and Hold Forever2 Beaten-Down Dividend Stocks to Buy and Hold Forever
fool.com - April 28 at 7:45 AM
Raymond James & Associates Has $358.47 Million Holdings in Abbott Laboratories (NYSE:ABT)Raymond James & Associates Has $358.47 Million Holdings in Abbott Laboratories (NYSE:ABT)
marketbeat.com - April 27 at 6:44 PM
Truist Financial Corp Sells 96,735 Shares of Abbott Laboratories (NYSE:ABT)Truist Financial Corp Sells 96,735 Shares of Abbott Laboratories (NYSE:ABT)
marketbeat.com - April 27 at 12:41 AM
Bella Vista teen drafted to Abbott HeartMates with Damar Hamlin as captainBella Vista teen drafted to Abbott HeartMates with Damar Hamlin as captain
msn.com - April 26 at 9:48 PM
Abbott Laboratories (NYSE:ABT) Position Reduced by Bank Julius Baer & Co. Ltd ZurichAbbott Laboratories (NYSE:ABT) Position Reduced by Bank Julius Baer & Co. Ltd Zurich
marketbeat.com - April 25 at 8:21 PM
Abbott Laboratories (ABT) "Buy" Rating Reiterated at Raymond JamesAbbott Laboratories' (ABT) "Buy" Rating Reiterated at Raymond James
americanbankingnews.com - April 24 at 1:36 AM
Schnieders Capital Management LLC Sells 17,738 Shares of Abbott Laboratories (NYSE:ABT)Schnieders Capital Management LLC Sells 17,738 Shares of Abbott Laboratories (NYSE:ABT)
marketbeat.com - April 23 at 11:17 PM
It’s Draft Day: Damar Hamlin Helps Build the Abbott HeartMates TeamIt’s Draft Day: Damar Hamlin Helps Build the Abbott HeartMates Team
finance.yahoo.com - April 23 at 6:11 PM
Abbott Laboratories (NYSE:ABT) Price Target Cut to $140.00 by Analysts at BarclaysAbbott Laboratories (NYSE:ABT) Price Target Cut to $140.00 by Analysts at Barclays
americanbankingnews.com - April 23 at 3:56 AM
Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Trims Stake in Abbott Laboratories (NYSE:ABT)Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Trims Stake in Abbott Laboratories (NYSE:ABT)
marketbeat.com - April 22 at 11:30 PM
Should You Pick Abbott Stock At $105 After An Upbeat Q1?Should You Pick Abbott Stock At $105 After An Upbeat Q1?
forbes.com - April 22 at 12:07 PM
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to KnowInvestors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
zacks.com - April 22 at 10:05 AM
Abbott Laboratories (NYSE:ABT) PT Lowered to $140.00 at BarclaysAbbott Laboratories (NYSE:ABT) PT Lowered to $140.00 at Barclays
marketbeat.com - April 22 at 8:41 AM
Why I Believe Abbott Is Much Better Positioned In Todays Rising Inflation ScenarioWhy I Believe Abbott Is Much Better Positioned In Today's Rising Inflation Scenario
seekingalpha.com - April 22 at 2:05 AM
Abbott Laboratories (NYSE:ABT) Expected to Earn Q2 2024 Earnings of $1.10 Per ShareAbbott Laboratories (NYSE:ABT) Expected to Earn Q2 2024 Earnings of $1.10 Per Share
americanbankingnews.com - April 22 at 1:52 AM
Commerzbank Aktiengesellschaft FI Boosts Position in Abbott Laboratories (NYSE:ABT)Commerzbank Aktiengesellschaft FI Boosts Position in Abbott Laboratories (NYSE:ABT)
marketbeat.com - April 21 at 5:13 PM
Austin weather: Gov. Abbott deploys emergency resources for severe weather threatAustin weather: Gov. Abbott deploys emergency resources for severe weather threat
fox7austin.com - April 20 at 7:45 PM
abrdn plc Boosts Stake in Abbott Laboratories (NYSE:ABT)abrdn plc Boosts Stake in Abbott Laboratories (NYSE:ABT)
marketbeat.com - April 20 at 12:11 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

AbbVie logo

AbbVie

NYSE:ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Abbott Laboratories logo

Abbott Laboratories

NYSE:ABT
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.